News

New annotated template EIC Pathfinder (2025)

Published on | 5 months ago

Programmes EIC

The EIC NCP Network Access2EIC  has published a new version (2025) of the Annotated Proposal Template  to Guide EIC Pathfinder Open 2025 Applicants.

The annotated template mirrors the official EIC Pathfinder Open proposal format but includes added layers of insight:

  • Blue text: Original proposal instructions from the European Commission.
  • Yellow highlights: Expert recommendations from EIC NCPs.
  • Light purple: “Tips & Tricks” from experienced proposal reviewers.
  • Light blue: Strategic insights from Timo Hallantie, Head of Unit for the EIC Pathfinder programme.

The Annotated Template can be found on the Access2EIC website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1728 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.